Iambic Therapeutics, a clinical-stage AI drugmaker backed by Nvidia, filed a registration statement for a U.S. public listing on Nasdaq under the ticker IAM, according to the company's SEC filing made public September 21.
The company uses generative AI to identify and develop drug candidates. Iambic's lead program, IAM1363, is currently in a Phase 1/1b clinical trial. The filing did not disclose a target valuation or IPO timing.
Iambic was founded to apply large language models and machine learning to target identification and drug design, a space that has drawn capital from both traditional venture funds and technology companies seeking exposure to AI-assisted therapeutics. Nvidia has positioned itself as an infrastructure supplier to AI drug discovery platforms, embedding its chips in the compute infrastructure used by biotech firms to screen and optimize molecular structures.
AI drug discovery remains early-stage as a commercial sector. Most AI-native biotech companies are still in preclinical or early clinical trials with lead programs. Exscientia, which went public on Nasdaq in 2021, has a single program in Phase 2 trials as of late 2024. Another AI platform, Absci, completed its SPAC merger in 2021 and has since shifted focus toward contract research services after slower clinical progress.
The SEC filing will be reviewed for the company's cash position, burn rate, intellectual property holdings, and the stage of its pipeline before the listing process advances. No underwriters or pricing details were disclosed in the initial filing.
Iambic's decision to pursue a public listing comes as venture funding for early-stage biotech has tightened and several AI therapeutics companies have struggled to advance programs from the lab to the clinic. The company will face investor scrutiny on whether its AI platform can produce drugs that clear clinical trials at a faster pace or lower cost than conventional drug discovery methods. The document to watch is the final prospectus, which will detail Iambic's historical R&D spending, capital requirements through clinical milestones, and the computational advantage its AI platform claims over traditional target discovery.
